ArticleEClinicalMedicine2026
Electroacupuncture for knee osteoarthritis: a multicentre randomised controlled trial assessing symptomatic and structural efficacy.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sympathetic regulation of bone homeostasis and remodeling: molecular mechanisms, pathophysiological roles, and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While electroacupuncture (EA) alleviates pain in knee osteoarthritis (KOA), high-quality evidence from large trials is limited, and its potential to influence structural progression is unknown. We investigated whether EA confers structural benefits beyond symptom relief. Methods: In this multicentre, randomised, parallel-group, sham-acupuncture (SA)-controlled trial at six Shanghai hospitals, eligible participants were assigned (1:1) to EA or SA, administered three times/week for six weeks, with 30-week follow-up. Patient enrolment occurred from November 30, 2021, to April 26, 2024, and the final follow-up was completed on November 22, 2024. The primary outcome was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) global score (0-240) at week 6. The minimal clinically important improvement (MCII) was predefined as a ≥12% relative improvement from baseline in the WOMAC global score. Key secondary outcomes included the WOMAC pain, stiffness, and function subscales, the Visual Analogue Scale (VAS), the Lequesne index, the Lysholm score, and the 6-Minute Walk Test (6MWT). Exploratory outcomes included artificial intelligence (AI)-based knee magnetic resonance imaging (MRI) measures of cartilage morphology and synovial inflammation. This trial was prospectively registered with the Chinese Clinical Trial Registry (ChiCTR2000036292). Findings: Of 686 assessed, 480 participants were randomised (EA: n = 240; SA: n = 240). At week 6, the EA group showed a significantly greater reduction in WOMAC global score than the SA group (adjusted mean change 65.35 vs 24.76, mean difference [MD]: 40.56, 95% CI 36.35-44.77; Interpretation: In patients with KOA, a 6-week course of EA provided substantial and durable symptomatic relief, representing a clinically meaningful therapeutic benefit. Exploratory MRI findings suggest that EA might have anti-inflammatory and cartilage-protective effects, but these structural signals require confirmation in trials specifically designed and powered for imaging endpoints. Funding: This work was supported by the National Natural Science Foundation of China (Key Program, Grant No. 82530121; General Program, Grant No. 82474534), the Shanghai Municipal Health Commission (Health Youth Talent Project, Grant No. 2022YQ025), the Science and Technology Commission of Shanghai Municipality (Medical Innovation Research Special Project, Grant Nos. 25Y12800800 and 23Y31920100), the Shanghai Oriental Talents Program (Leading Talent Project), the Traditional Chinese Medicine Innovation Team and Talent Support Program-National Traditional Chinese Medicine Multidisciplinary Cross-Innovation Team Project (ZYYCXTD-D-202401), and the Shanghai Triennial Initiative for Promoting Clinical Proficiency and Innovation Capabilities in Municipal Hospitals (Grant No. SHDC2020CR1010A).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.